Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

DEQUALINIUM FOR SYSTEM SUITABILITY CRS (20 MG)

DEQUALINIUM FOR SYSTEM SUITABILITY CRS (20 MG)

ND

DISCOVER
DIOSMIN FOR SHEPHERD'S PURSE CRS (40 MG)

DIOSMIN FOR SHEPHERD'S PURSE CRS (40 MG)

ND

DISCOVER
ETODOLAC IMPURITY MIXTURE CRS(0.009 MG)

ETODOLAC IMPURITY MIXTURE CRS(0.009 MG)

ND

DISCOVER
LEVOMEPROMAZINE FOR SYSTEM SUITABILITY CRS (15 MG)

LEVOMEPROMAZINE FOR SYSTEM SUITABILITY CRS (15 MG)

NA

DISCOVER
METHYLENE CHLORIDE - REFERENCE SPECTRUM (N/A)

METHYLENE CHLORIDE - REFERENCE SPECTRUM (N/A)

ND

DISCOVER
CROTAMITON FOR SYSTEM SUITABILITY CRS (1 MG)

CROTAMITON FOR SYSTEM SUITABILITY CRS (1 MG)

ND

DISCOVER
HYDROXYETHYL SALICYLATE IMPURITY C CRS (100 MG)

HYDROXYETHYL SALICYLATE IMPURITY C CRS (100 MG)

ND

DISCOVER
ENOXOLONE FOR PEAK IDENTIFICATION CRS (15 MG)

ENOXOLONE FOR PEAK IDENTIFICATION CRS (15 MG)

ND

DISCOVER
ENOXOLONE IMPURITY A CRS (15 MG)

ENOXOLONE IMPURITY A CRS (15 MG)

ND

DISCOVER
DICLAZURIL CRS (15 MG)

DICLAZURIL CRS (15 MG)

ND

DISCOVER
BENZYDAMINE IMPURITY G CRS (15 MG)

BENZYDAMINE IMPURITY G CRS (15 MG)

ND

DISCOVER
RHUBARB ROOT DRY EXTRACT FOR SYSTEM SUITABILITY HRS (310 MG)

RHUBARB ROOT DRY EXTRACT FOR SYSTEM SUITABILITY HRS (310 MG)

ND

DISCOVER